Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis

The monoclonal antibody tildrakizumab, sold by Sun Pharma as Ilumya, is more cost-effective for treatment of moderate-to-severe psoriasis than a half dozen competitors, including top-selling adalimumab (Humira), according to data…

Continue Reading Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis

Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis

Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity compared to…

Continue Reading Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis